Niowave has entered into a new agreement with Novartis to supply Actinium-225, a highly promising medical isotope The long-term supply agreement supports the development of next-generation therapies ...
NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into ...
BELLEVUE, Wash.--(BUSINESS WIRE)--TerraPower Isotopes announced today it is producing actinium-225 1 at commercial-scale, providing sustained access to highly pure actinium-225 to the global ...
DUBLIN, Ohio, April 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced a significant expansion of its Actinium-225 (Ac-225) production capabilities at the company's Center for ...
$450 million East Coast flagship cGMP facility will increase Ac-225 production capacity twentyfold, supporting the next generation of cancer therapies PHILADELPHIA, May 6, 2026 /PRNewswire/ -- ...
Actinium Pharmaceuticals, Inc. (ATNM) stock was in the spotlight on Friday after the company announced promising new preclinical findings for its novel radiotherapy, ATNM-400, at the 2025 San Antonio ...
The MarketWatch News Department was not involved in the creation of this content. -- Niowave has entered into a new agreement with Novartis to supply Actinium-225, a highly promising medical isotope - ...